In a surprising twist to Alzheimer’s research,a new study published in Cell suggests a potential link between certain cancers and a reduction in the disease’s hallmark brain lesions. Scientists have discovered that a protein released by lung, colon, and prostate tumors-cystatin C-appears to activate the brain’s immune cells, potentially clearing amyloid plaques associated with Alzheimer’s disease. While still preliminary, the findings offer a novel avenue for therapeutic exploration in a condition affecting millions globally and currently without a cure.
L’ESSENTIEL
- According to a new study, lung, colon, and prostate cancers may reduce the lesions associated with Alzheimer’s disease.
- A protein secreted by these tumors activates brain immune cells and eliminates amyloid plaques.
- Amyloid plaques, along with neurofibrillary tangles, are the two types of lesions that affect patients with Alzheimer’s disease.
Cancer may hold a surprising key to treating Alzheimer’s disease, according to new research published in the journal Cell. Researchers have discovered that a protein released by certain tumors can activate the brain’s immune cells, potentially clearing the amyloid plaques characteristic of Alzheimer’s.
Tumors Appear to Reduce Alzheimer’s Disease Lesions
Alzheimer’s disease is a neurodegenerative condition caused by two primary types of brain damage: amyloid deposits and neurofibrillary tangles. Both disrupt brain function, leading to memory loss. Currently, there is no cure for Alzheimer’s disease, but this new study suggests cancer could act as a “biological cleanser” for these damaging lesions. Understanding the underlying mechanisms of Alzheimer’s is crucial as the disease affects millions worldwide and places a growing burden on healthcare systems.
In their experiments, scientists transplanted three types of tumors – lung, colon, and prostate – into mice with Alzheimer’s disease. They observed a significant reduction in amyloid plaques in the brains of the mice. All three tumor types released a specific protein called cystatin C (Cyst-C). Researchers found that Cyst-C was able to cross the blood-brain barrier and enter the brain. Once inside, Cyst-C activated the microglia, which are immune cells residing in the brain responsible for protecting it by eliminating harmful agents. However, in Alzheimer’s disease, microglia lose their function, and no current treatment can reactivate or replace them… except, perhaps, Cyst-C, which the study suggests can restore their activity.
Cyst-C Protein Linked to Improved Memory
Beyond the scientific observations, researchers wanted to measure the real-world impact on the mice. They tested the mice’s memory in a water maze, both before and after administering a Cyst-C protein treatment. The rodents had to remember the location of a hidden platform to escape the water. Results showed that the mice initially struggled to find the platform, but with the Cyst-C treatment, they navigated to it much more quickly, indicating a real improvement in symptoms and quality of life.
“Our findings represent a significant conceptual advance in the field of cancer neuroscience and open up distinct therapeutic avenues from current strategies for reducing amyloid, aiming to degrade existing amyloid plaques for precision therapy against Alzheimer’s disease,” said Youming Lu, the lead author of the study, in a statement.
However, the beneficial effect of the Cyst-C molecule still needs to be confirmed before it can be validated. Cancer remains one of the most widespread and deadly diseases in France. According to the National Cancer Institute (INCa), the number of new cases doubled between 1990 and 2023, representing a 98% increase in men and a 104% increase in women across all locations.
Consult our digital video work,
only an account creation is required to access it.
